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Abstract
Objective This study was carried out to determine the potential role of the M2/ANXA5 haplotype as a risk factor for recurrent
implantation failure (RIF). Carriage of the M2/ANXA5 haplotype that induces prothrombotic changes has been implicated in
failure of early pregnancies and placenta-mediated complications (preeclampsia, IUGR, preterm birth).
Material and methods In the present case control study, 63 couples (females and males) with RIF presenting for IVF/ICSI to the
Fertility Center of [masked] were analyzed. RIF was defined as ≥ 4 consecutive failed ART-transfers of ≥ 4 blastocysts or ≥ 8
cleavage-stage embryos of optimal quality and maternal age ≤ 41. Fertile female controls (n = 90) were recruited from the same
center. Population controls (n = 533) were drafted from the PopGen biobank, UKSH Kiel.
Results Couples carrying the M2/ANXA5 haplotype turned out to have a significantly increased relative risk (RR) for RIF.
Compared with female fertile controls, RR was 1.81 with p = 0.037 (OR 2.1, 95%CI 1.0–4.3) and RR was 1.70, with p = 0.004
(OR 2.0, 95%CI 1.2–3.1) compared with population controls (15.4% M2 carriers). Male partners were comparable with RIF
females for M2/ANXA5 haplotypes (28.6% vs. 23.8%, p = 0.54). RIF females compared with population controls had a RR of
1.55 (p = 0.09) and RIF males compared with population controls had a RR of 1.9 (p = 0.01). Couples with ≥ 7 failed transfers
showed a RR of 1.82 (p = 0.02) compared with population controls.
Conclusion Our findings suggest that maternal as well as paternalM2/ANXA5 haplotype carriages are risk factors for RIF. These
results allow new insights into the pathogenesis of RIF and might help to identify relevant risk groups.
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Introduction
Recurrent implantation failure (RIF) is determined when mor-
phologically good quality embryos repeatedly fail to implant
after numerous IVF/ICSI treatment attempts [1–5].
There are several variations to the criteria for defining RIF
[2]. Some definitions include the numbers of failed ART
cycles and the numbers of transferred embryos. For example,
Polanski et al. assess RIF as ≥ 2 consecutive unsuccessful
transfers with ≥ 4 embryos or 2 blastocysts of high quality
[6]. Others include female age as an additional criterion [1,
3–7], such as the European Society for Human Reproduction
and the Embryology (ESHRE) PGD Consortium [4, 5]. They
define RIF as ≥ 3 transfers in women under 37 years or, re-
spectively, ≥ 2 transfers in women above 37 years after trans-
fers of 10 good quality embryos. Considering the current suc-
cess rate of an ART attempt, the number and quality of em-
bryos transferred, and the female age, we defined RIF as ≥ 4
failed consecutive ART transfers of ≥ 4 blastocysts or ≥ 8
cleavage stage embryos of good quality in women ≤ 41 years.
Human implantation is a complex process requiring syn-
chrony between a healthy embryo that should have the poten-
tial to implant and a functionally competent and receptive
endometrium [8]. A successful development is the result of a
coordinated “cross-talk” between the embryo and the
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endometrium, which leads to the apposition, attachment, and
invasion of the embryo into the receptive uterine stroma [2, 8].
Any abnormality will result in an implantation failure.
Despite extensive efforts and research on fundamental
causes for RIF, the understanding of this condition is still
limited [9]. Frequently, the embryo and its ploidy status have
been considered [9, 10]. Failure of implantation due to embry-
onic causes is associated with either genetic abnormalities or
other factors that impair the embryo to develop in utero, to
hatch, and to implant [2, 3]. Likewise, maternal factors were
suggested to play an essential role for RIF [1–3, 10]. For
example, uterine abnormalities [2, 11, 12], thrombophilias
[3, 13–16], immunological factors [1–5], the antiphospholipid
syndrome, parental genetic disorders [3, 10], and endometrial
factors, particularly the receptivity with the window of im-
plantation, were proposed [4, 17–22]. Nevertheless, the ma-
jority of RIF cases still remain unexplained [1, 2, 10].
Since 2007, much work has been accumulated on a newly
identified hereditary thrombophilic genetic factor, the ‘M2
haplotype’ of the annexin A5 (ANXA5) gene. Indeed, we
and others identified the M2 haplotype associated with obstet-
ric pathologies such as gestational hypertension, preeclampsia
[23–27], fetal growth restriction, preterm birth [26, 28–30],
antiphospholipid syndrome [31], and most incriminatory re-
current pregnancy losses (RPL) [32]. Moreover, in our previ-
ous studies, we confirmed risks of maternal M2/ANXA5 hap-
lotype and identified the paternal carrier status as an equal risk
factor for RPL and obstetric complications [23, 33].
The M2/ANXA5 haplotype results in a reduced expression
of ANXA5 products usually expressed at the apical surface of
the syncytiotrophoblast (SCT) [25, 26, 34], facing the
intervillous space and floated with maternal blood [35].
Thus, ANXA5 accomplishes its anticoagulant function neces-
sary for the hemodynamic balance in the placenta and preg-
nancy, thereby decreasing phospholipid availability for the
cascade of coagulation factors [36–39]. As a successful im-
plantation requires a balance of pro- and anticoagulatory
mechanism at the embryo-maternal interface and within the
placenta, ANXA5 is indispensable for the process of implan-
tation. Anti-annexin A5 antibodies (anti-ANXA5) have been
identified to influence and even inhibit the essential functions
of the ANXA5, particularly affecting implantation.
Matsubayashi et al. demonstrated that RIF patients produce
anti-ANXA5 significantly more often than controls (8.3% vs.
1.1%, p < 0.05) and consequently postulate anti-ANXA5 an-
tibodies as risk factor for RIF [40]. Currently, there is only one
multicenter study by Fishel et al. analyzing the M2/ANXA5
haplotype in infertility couples undergoing ART procedure
[41]. They reported a M2 carrier status of 44% in IVF couples
(n = 157; one or both partners), 24% of females, 26% of
males, and 37% of couples with unexplained infertility [41].
In spite of these intruiging results, the relevance ofM2/ANXA5
for RIF has not yet been studied.
Therefore, the primary objective of this study was to inves-
tigate, whether the maternal and/or the paternal M2/ANXA5
carriage are risk factors for RIF. As a second objective, we
aimed to find new insights into the pathogenesis of RIF to
identify relevant risk groups. With regard to these goals, we
investigated the prevalence of M2/ANXA5 in a well-defined




In this present case control study, RIF was defined as ≥ 4 con-
secutive failed ART-transfers of ≥ 4 blastocysts or ≥ 8 cleavage-
stage embryos of optimal quality and maternal age ≤ 41.
Study populations and controls
The study population of 63 couples (63 females and 63 males)
with a history of recurrent implantation failure was recruited
between May 2016 and May 2019 in the Division of
Gynecological Endocrinology and Reproductive Medicine
of the [masked for blinded review] University. All individuals
studied were from European origin, mainly German. After
clarification and written informed consent, blood was drawn
and DNA was extracted from white blood cells using the
QIAmp DNA blood mini kit (Qiagen, Hilden, Germany) and
stored in 100-μl aliquots at − 20 °C for further analyses.
Biographic and historic data of RIF couples (RIF females
and RIF males) and [masked for blinded review] fertile con-
trols are illustrated in Table 1. The study cohort was composed
as follows: 11 couples already terminated the fertility treat-
ment and were contacted for the purpose of this study; 52
couples were still in treatment. Indications for the fertility
treatment are illustrated in Fig. 1.
In total, 309 embryo transfers (ET) were performed, and
altogether, 556 embryos were transferred. Out of the 309 ET,
154 transfers were fresh ET with 155 (53.5%) day 5 trans-
ferred blastocysts and 136 (46.7%) day 3 transferred cleavage
stages. The remaining 155 transfers were frozen-thawed ET
with totally 195 (73.6%) transferred blastocysts (d5 transfers)
and 70 (26.4%) cleavage stages (d3 transfers). Regarding the
number of transferred embryos, 62 (11.2%) single ET and 494
(88.8%) double ET were carried out.
The study group was compared with two independent con-
trol groups:
(1) 90 fertile women with inconspicuous timespan to con-
ception (< 10 months), uncomplicated pregnancies, no
gestational pathologies, at least one spontaneous term
delivery of a healthy normal weight singleton, and no
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miscarriages. This fertile control group was aged be-
tween 18 and 41 years and showed a BMI of 19 to 30
kg/m2 according to the study population. They were re-
cruited between May 2016 and May 2019 in the outpa-
tient clinic of the Department of Gynecology and
Obstetrics, [masked for blinded review] University
([masked for blinded review] controls). Biographic data
and gestational history of the [masked for blinded re-
view] controls are shown in Table 1.
(2) Previously recruited German control group representing
a population control sample drafted from the PopGen
biobank at the University Clinic Schleswig-Holstein
Kiel (n = 533) [42]. The PopGen population controls
were from Northwest Germany, federal state of
Schleswig-Holstein, and consisted of healthy subjects
identified through official population registers. The sam-
ple used in this study consisted of about equal numbers
of men and women, distributed among the three age
groups (18–30, 30–50, 50–80 years).
Study criteria and RIF screening
The study criteria (inclusion and exclusion criteria) are sum-
marized in Table 2.
All patients had undergone an extensive diagnostic work
up to identify any potential cause for RIF before study inclu-
sion. If any potential reason was detected, it was eliminated, if
this was possible and a benefit could be expected; otherwise
patients were excluded. In brief, the following factors were
screened: uterine anomalies were clarified by hysteroscopy.
Endometrial receptivity analysis (ERA) was carried out by
endometrial biopsy in a non-treatment cycle before embryo
transfer to identify the window of implantation.
Endocrinologic dysfunctions (polycystic ovary syndrome ac-
cording to the Rotterdam criteria [43], hyperprolactinemia,
hyperandrogenemia, thyroidal dysfunctions such as hypo-/
hyperthyreosis and thyroid autoantibodies), autoimmune disor-
ders (antinuclear antibodies > 1:240), inherited thrombophilias
(factor V-Leiden mutation, the prothrombin 20210G>A), and
deficiencies in coagulation factors (protein C, protein S, factor
XII, antithrombin) were excluded. An antiphospholipid syn-
drome was ruled out according to the international consensus
Table 1 Biographic and historic data of the RIF couple subclassified in females and males vs. [masked for blinded review] fertile controls
RIF females (n = 63) RIF males (n = 63) [masked for blinded review]
fertile controls
p
Age (year) 35 ± 3 (26–41) 39 ± 5 (27–50) 34 ± 5 (21–41) 0.049
Body mass index (kg/m2) 23 ± 2 (19 - 30) - - -
Pregnancies (n) 0.2 ± 0.5 (0–2) - 2 (1–5) < 0.0001
Deliveries (n) 0.0 ± 0.2 (0–1) - 2 (1–5) < 0.0001
Miscarriages (n) 0.1 ± 0.4 (0–2) --- 0 < 0.0001
Ectopic pregnancies (n) 0.0 ± 0.2 (0–1) --- 0 < 0.0001




























Fig. 1 Indications for fertility
treatment of the RIF couples
subdivided in female and male
indications. RIF: recurrent
implantation failure. Created with
CorelDraw Home&Student X8
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statement on an update of the classification criteria for definite
antiphospholipid syndrome [44]. Parental genetic disorders
were clarified by genetic counseling and karyotype testing of
the couples. In case of a chromosomal anomaly, a preimplan-
tation genetic screening (PGS) was offered and carried out
after approval by a nominated and qualified ethic
committee.
Ethical approval
The study complied with the ethical guidelines of the institu-
tions involved and was approved of the Review Board of the
[masked for blinded review] University (IRB 238-16).
Informed consent was obtained from all patients and controls.
The criteria of strengthening the reporting of observational
studies in epidemiology [45] were observed as far as
applicable.
Genotyping and statistical analysis
The extracted DNAwas genotyped through amplicon sequenc-
ing as previously described [46]. The genotypes were recorded
in table format and coded for further usage. Odds ratios (OR)
with 95% confidence intervals (CI) were calculated by using
the FREQ procedure intrinsic to the SAS statistical software
package, version 9 (SAS Institute, Cary, NC, USA).
Departures from the Hardy-Weinberg equilibrium were com-
puted by a Markov Chain Monte Carlo (MCMC) implementa-
tion of an exact test, as part of the Genepop package [47].
Results
In total, 63 couples with RIF were investigated and compared
with 90 fertile female controls ([masked for blinded review]
controls) and with 533 population controls (PopGen controls).
The study group was in Hardy-Weinberg equilibrium for the
ANXA5 haplotypes (RIF couples: MCMC P = .2090, RIF
females: MCMC P = .3378, RIF males: MCMC P = .4703)
as well as both control groups [masked for blinded review]
controls (MCMC P = .1150) and PopGen controls (MCMC
P = .409), respectively. The genetic frequency of M2
(Table 3) was found to be considerably higher in RIF patients
(RIF couples: 0.143, RIF females: 0.127, RIF males: 0.159)
than in [masked for blinded review] controls (0.083) and pop-
ulation controls (0.082).
M2 carriers presented a 1.8-fold elevated risk for RIF (OR
2.1, 95%, CI 1.0–4.3) compared with noncarriers. In compar-
ison with the PopGen control group (n = 533), similar results
were obtained (Table 4). Results regarding RR and OR of the
M2/ANXA5 carriership of RIF couples, subclassified in RIF
females and RIF males compared with [masked for blinded
Table 2 Study criteria
Signed informed consent




BMI > 19 < 30 kg/m2
Non-smoker
No intake of medications for
systematic diseases
e.g., anti-epileptics, anti depressives
No infectious diseases Hepatitis, HIV, tuberculosis
RIF recurrent implantation failure, BMI body mass index (calculated
as weight in kilograms divided by the square of height in meters)
Table 3 Genotype frequencies of ANXA5 gene promoter haplotypes in European RIF couples, RIF females and RIF males, and different control
groups
Index RIF couples RIF females RIF males [masked for blinded review]
fertile controls
PopGen controls
Genotype Observed Expecteda Observed Expecteda Observed Expecteda Observed Expecteda Observed Expecteda
N/N 75 (59.5) 73.8 41 (65.1) 41.2 34 (54.0) 32.8 62 (68.9) 60 415 (77.9) 413.3
N/M1 15 (11.9) 17.7 6 (9.5) 6.5 9 (14.2) 10.9 15 (16.7) 14.8 35 (65.7) 47.8
M1/M1 3 (2.4) 1.0 1 (1.6) 0.2 2 (3.2) 0.8 0 0.8 1 (0.2) 1.5
N/M2, M1/M2b 30 (23.8) 31.0 14 (22.2) 14.1 16 (25.2) 17.0 11 ( 12.2) 13.8 77 (14.4) 79.9
M2/M2 3 (2.4) 2.5 1 (1.6) 1.0 2 (3.2) 1.5 2 (2.2) 0.6 5 (0.9) 1.4
Total 126 126 63 63 63 63 90 90 533 533
Note: Values are number (percentage)
N wild type, M1M1-haplotype, M2 M2-haplotype
a Expected: genotype frequency expected at Hardy-Weinberg equilibrium, calculated with the Genepop package
bGenotype M1/M2 was only observed in two RIF males, in three [masked for blinded review] fertile controls and five PopGen controls
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review] fertile controls and PopGen controls, are illustrated in
Table 4.
RIF couples as well as RIF males showed significantly
higher RR and OR forM2/ANXA5 carriership compared with
both control groups (RIF couples vs. [masked for blinded
review] fertile controls: RR 1.81; p = 0.037, respectively, vs.
PopGen controls: RR 1.70; p = 0.004; RIF males vs. PopGen
controls: RR 1.86; p = 0.008) (Table 4).
Subanalysis revealed 15 RIF females (1 homozygote) and
18 RIF male partners (2 homozygotes) being M2 carriers
(Table 3). Thus, the genetic risk transmitted by maternal and
paternal alleles turns out to be comparable. As men were
showing higher AF, the sample size was too small (n = 63)
to draw further conclusions.
Interestingly, RIF couples with idiopathic infertility and
RIF couples with higher grade RIF (≥ 7 failed transfers)
showed significantly increased RR and OR compared with
PopGen controls (RR 2.0, OR 2.44; p = 0.043, respectively,
RR 1.82, OR 2.14; p = 0.021).
Couples with idiopathic infertility presented M2/ANXA5
non-significantly more often than couples with identified in-
dication for ART (30.8% vs. 25.0%, p = 0.55).
Discussion
Our study strongly supports an association of theM2/ANXA5
haplotype with RIF. The obtained results suggest an active
role of the haplotype in RIF events. Our findings of equal
maternal (23.8%) and paternal (28.6%) M2 carriership sug-
gest embryonic and possibly maternal factors.
Highly ordered 2D arrays of ANXA5 have been found to
be indispensable for membrane repair in murine perivascular
cells [48, 49]. Further investigations confirmed this finding in
human cyto- and syncytiotrophoblasts [50]. Additional stud-
ies showed that 2D arrays of ANXA5 are essentially involved
in the regulation of trophoblast aggregation to form syncytia.
Hence, this 2D network of ANXA5 is essential for successful
fusion of cells [51]. Villous cytotrophoblasts fuse throughout
pregnancy to form multinucleated syncytia on chorionic villi
that extends into the maternal placental blood circulation to
form an interphase allowing effective exchange of gases and
nutrients in the intervillous chamber [52]. Moreover, these
multinucleated syncytia produce and secrete pregnancy-
specific hormones [53], such as hCG [54], that are of pivotal
importance for implantation, placentation, and subsequently, a
successful pregnancy. Also, the cellular fusion and membrane
repair events are of importance for a successful embryonal
implantation at the forming of the cell-to-cell interphase com-
posed of extraembryonic and endometrial receptive mem-
branes to trigger the necessary programs of early placentation.
It would be then logical to propose that paternal (embryonic)
and maternal factors would have about equal bearing in these
processes. A reduced expression of ANXA5 in carriers of the
M2 haplotype may disturb cell fusion and membrane repair
ultimately leading to implantation failure.
To our knowledge, this is the first study on the role ofM2/
ANXA5 in RIF. Previously, it has been demonstrated that the
haplotype was a risk factor for infertility in IVF cohorts [41,
55]. In this context, the authors demonstrated in 2014 that
IVF-treated couples (n = 157) with infertility had significantly
increased M2 carriage, whereas maternal and paternal car-
riages impose an equal risk [41]. In the light of its importance
for patients with RPL and potentially implantation failure, the
study has assessed the incidence of carrier status for the M2/
ANXA5 haplotype in both the female and male of couples with
at least one failed IVF cycle. In 314 patients (157 couples),
44% of couples (one or both partners), 24% of females, 26%
of males, and 37% of couples with unexplained infertility
were M2 carriers [41]. This rather high incidence inspired
further more dedicated studies on specific patient populations
and the value of post embryo-transfer therapy. Couples (n =
Table 4 Relative risks and odds ratios of the M2 carriage of RIF couples, RIF females and RIF males compared with [masked for blinded review]
fertile controls and PopGen controls
RR [95% CI] OR [95% CI] p
RIF couples [masked for blinded review] fertile controls 1.81 [1.01–3.25] 2.10 [1.03–4.27] 0.037
PopGen controls 1.70 [1.19–2.42] 1.95 [1.23–3.10] 0.004
RIF females [masked for blinded review] fertile controls 1.65 [0.84–3.22] 1.85 [0.81–4.23] 0.141
PopGen controls 1.55 [0.95–2.51] 1.72 [0.92–3.21] 0.087
RIF males [masked for blinded review] fertile controls 1.98 [1.05–3.73] 2.37 [1.06–5.29] 0.027
PopGen controls 1.86 [1.20–2.88] 2.20 [1.21–3.99] 0.008
RIF couples with idiopathic infertility [masked for blinded review] fertile controls 2.13 [0.99–4.58] 2.63 [0.95–7.29] 0.057
PopGen controls 2.00 [1.09–3.68] 2.44 [1.03–5.81] 0.043
Higher-grade RIF (≥ 7 failed transfers)) [masked for blinded review] fertile controls 1.94 [0.99–3.79] 2.30 [0.98–5.40] 0.052
PopGen controls 1.82 [1.12–2.96] 2.14 [1.10–4.14] 0.021
RIF recurrent implantation failure, RR relative risk, OR odds ratio, CI confidence interval
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77) with one or both partners carrying M2/ANXA5 showed a
correlation of this haplotype with an adverse IVF outcome
[55]. A pragmatic, multicenter, prospective cohort study of
M2/ANXA5 haplotype screening, and low molecular weight
heparin (LMWH) treatment following embryo transfer in
103 IVF couples positive for M2 was conducted. They were
compared with a group of 1000 contemporaneous randomly
selected unscreened and untreated couples undergoing
assisted conception, from which 103 matched control couples
were extracted. The primary outcome measure was live birth
incidence. Secondary outcomeswere results following ET and
live birth outcome by gender and M2 carriage and allelic dose
influence. In the result, the tested and treated cohort of M2/
ANXA5 carriers reached a similar live birth rate (37.9%) per
ET cycle compared with both, the more fertile comparison
group (38.5%) and the 103 matched controls (33.0%).
Significantly more treated male carrier only couples had a live
birth of 58.3% vs. 25.0% (p = 0.045) versus female M2. Thus,
pragmatic M2/ANXA5 screening and treatment with LMWH
in couples undergoing IVF were associated with similar out-
come to couples with more beneficial prognostic factors. The
difference in live birth outcome for treated male-only carrier
couples may be consistent with an additional maternal
thrombophilic factor that may adversely affect pregnancy, al-
though other mechanisms, such as LMWH dosage effect, are
feasible. This study suggested that LMWH treatment should
be started prior to clinical pregnancy.
A very recent report identified alternative means of
supplementing anticoagulation, through elevated ANXA5 ex-
pression [56]. Physiological micromolar Zn2+ stimulated
ANXA5 transcription, raising ANXA5 protein expression
and surface abundance on choriocarcinoma human placental
cells (BeWo) and human umbilical vein endothelial cells
(HUVEC), thus resulting in extended coagulation times. In
this study, Zn2+-fed AnxA5 functionally deficient pregnant
mice exhibited a trend to increase litter size when primiparous
that grew similarly to wild-type progeny in subsequent preg-
nancies. A raised AnxA5 signal upon Zn2+ treatment was
confirmed in murine placentae. Micromolar Zn2+ stimulated
ANXA5 expression in cell culture directly and attenuated
RPL in AnxA5 genetically deficient mice, without notable
toxicity effects.
However, currently, there is no consistent definition of
RIF. Some authors include the number of failed ART-cycles
and the number of transferred embryos as criteria for defining
RIF. Others, additionally, include the female age [1, 3–7, 10].
The ESHRE guideline addresses female age (< 37 years and >
37 years), however, without an upper limit. As clinical preg-
nancy rate per embryo transfer decreases from 20.8% in wom-
en at the age of 41 years to 17.7% at the age of 42 and the rate
of aneuploid oocytes increases from about 57% to 68% [57,
58], we included the female age and set the cutoff at the female
age of ≤ 41 years. Considering the current success rate of an
ART attempt, the number and quality of embryos transferred
as well as the female age, we defined RIF as ≥ 4 failed con-
secutive ART transfers of ≥ 4 blastocysts or ≥ 8 cleavage stage
embryos of good quality in women ≤ 41 years. With these
more refined RIF criteria, we think we can substantially in-
crease the significance of our study.
Furthermore, to discuss the advantages of our novel ap-
proach, we refer to the well-defined study group including
63 infertile couples of 63 women as well as 63 men compared
with two control groups: one unselected, large population
control of 533 females andmales in equal parts and one fertile,
female control group of 90 participants. All investigated indi-
viduals were from European origin; thus, possible interference
caused by ethnic differences was excluded. Additionally, to
meet the strict study criteria, all patients had undergone an
extensive diagnostic work-up for selecting unexplained RIF,
including genetic counseling and karyotype testing. A possi-
ble weakness of this study should be mentioned at this point,
that routine pre-implantation genetic screening was not per-
formed due to legal restrictions and therefore the genetic ploi-
dy status of the transferred embryos remained unknown.
As a matter of fact, multiple failed cycles can leave couples
frustrated and desperate for explanations. It is therefore nec-
essary to determine the etiologies of RIF in order to propose
new and beneficial solutions for these patients.
Our findings suggest that maternal and paternal M2/
ANXA5 haplotype carriages are risk factors for RIF. These
results allow new insights into the pathogenesis of RIF and
might help to identify relevant risk groups. Further studies are
needed to confirm our assumption. As well, therapeutic op-
tions have to be identified and established.
Conclusion
Deficiency of ANXA5 through maternal or paternal
carriership of the M2 haplotype is proposed as a risk factor
for recurrent implantation failure.
This finding represents a possible explanation for implan-
tation failure after IVF/ICSI as well as for the absence of
spontaneous conceptions. Our results provide new insights
into the pathogenesis of RIF and could be used to identify
patients at risk.
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